A Phase II Study of Cefepime Monotherapy for Febrile Neutropenia in Patients with Lung Cancer
Not Applicable
- Conditions
- Febrile neutropenia in patients with lung cancer
- Registration Number
- JPRN-UMIN000006157
- Lead Sponsor
- Central Japan Lung Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Not provided
Exclusion Criteria
1) Infection in which the study drug is considered to be ineffective 2) Medical history of anaphylaxis or hypersensitivity to beta-lactams 3) Positive skin test to the study drug if skin testing is performed 4) Sings and symptoms of shock 5) Mycobacterial, fungal, rickettsial, viral, chlamydial, parasitic or protozoal infection 6) Prior history of antimicrobial therapy (prophylaxis with trimethoprin-sulfapethoxazole is excluded) within the past 14 days 7) Pregnant or nursing
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method